Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
Molecular Cancer Therapeutics
|
July 23, 2008
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms
Zhong Chen, Justin L Ricker, Pramit S Malhotra, et al.
Investigational New Drugs
|
October 26, 2007
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R Blumenschein, Merrill S Kies, Vassiliki A Papadimitrakopoulou, et al.
Cancer Science
|
October 13, 2009
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Takashi Watanabe, Harumi Kato, Yukio Kobayashi, et al.
Blood
|
September 9, 2006
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
Madeleine Duvic, Rakshandra Talpur, Xiao Ni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A Olsen, Youn H Kim, Timothy M Kuzel, et al.
Cancer Research
|
September 18, 2004
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma
Amy Loercher, Tin Lap Lee, Justin L Ricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer
Eric H Rubin, Nancy G B Agrawal, Evan J Friedman, et al.
Clinical Lymphoma & Myeloma
|
December 3, 2009
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma
Madeleine Duvic, Elise A Olsen, Debra Breneman, et al.
Clinical Colorectal Cancer
|
July 29, 2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
Bert H O'Neil, Calin Cainap, Eric Van Cutsem, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 2, 2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib
Evelyn M McKeegan, Peter J Ansell, Gerard Davis, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
Molecular Cancer Therapeutics
|
July 23, 2008
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms
Zhong Chen, Justin L Ricker, Pramit S Malhotra, et al.
Investigational New Drugs
|
October 26, 2007
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R Blumenschein, Merrill S Kies, Vassiliki A Papadimitrakopoulou, et al.
Cancer Science
|
October 13, 2009
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Takashi Watanabe, Harumi Kato, Yukio Kobayashi, et al.
Blood
|
September 9, 2006
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
Madeleine Duvic, Rakshandra Talpur, Xiao Ni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A Olsen, Youn H Kim, Timothy M Kuzel, et al.
Cancer Research
|
September 18, 2004
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma
Amy Loercher, Tin Lap Lee, Justin L Ricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer
Eric H Rubin, Nancy G B Agrawal, Evan J Friedman, et al.
Clinical Lymphoma & Myeloma
|
December 3, 2009
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma
Madeleine Duvic, Elise A Olsen, Debra Breneman, et al.
Clinical Colorectal Cancer
|
July 29, 2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
Bert H O'Neil, Calin Cainap, Eric Van Cutsem, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 2, 2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib
Evelyn M McKeegan, Peter J Ansell, Gerard Davis, et al.
Page
of 3